Back to results
US 12,180,281 B2Granted
Anti-PD-1 antibodies and methods of treating cancer
AssigneeBiocytogen Pharmaceuticals (Beijing) Co., Ltd.
InventorsYi Yang, Chunyan Dong, Fang Yang, Chengyuan Lu, Yuelei Shen, Jian Ni, Yanan Guo, Yunyun Chen, Jingshu Xie
Life of this patent
Estimating the term…
Abstract
This disclosure relates to anti-PD-1 (Programmed Cell Death Protein 1) antibodies, antigen-binding fragments, and the uses thereof.
Claims30
A method of treating cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of
- an antibody or antigen-binding fragment thereof that binds to PD-1 (Programmed Cell Death Protein 1) comprising:
- a heavy chain variable region (VH) comprising complementarity determining regions (CDRs) 1, 2, and 3;
- and
- a light chain variable region (VL) comprising CDRs 1, 2, and 3,
- wherein the VH CDRs 1, 2, and 3 amino acid sequences and the VL CDRs, 1, 2, and 3 amino acid sequences are one of the following:
- (1) the VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs:
- 1, 2, 3, respectively, and the VL CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs:
- 4, 5, 6, respectively;
- and
- (2) the VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs:
- 19, 20, 21, respectively, and the VL CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs:
- 22, 23, 24, respectively.
9 more elements
A method of decreasing the rate of tumor growth, the method comprising
- contacting a tumor with an effective amount of
- an antibody or antigen-binding fragment thereof that binds to PD-1 comprising:
- a VH comprising CDRs 1, 2, and 3;
- and
- a VL comprising CDRs 1, 2, and 3,
- wherein the VH CDRs 1, 2, and 3 amino acid sequences and the VL CDRs, 1, 2, and 3 amino acid sequences are one of the following:
- (1) the VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs:
- 1, 2, 3, respectively, and the VL CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs:
- 4, 5, 6, respectively;
- and
- (2) the VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs:
- 19, 20, 21, respectively, and the VL CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs:
- 22, 23, 24, respectively.
10 more elements
A method of killing a tumor cell, the method comprising
- contacting a tumor cell with an effective amount of
- an antibody or antigen-binding fragment thereof that binds to PD-1 comprising:
- a VH comprising CDRs 1, 2, and 3;
- and
- a VL comprising CDRs 1, 2, and 3,
- wherein the VH CDRs 1, 2, and 3 amino acid sequences and the VL CDRs, 1, 2, and 3 amino acid sequences are one of the following:
- (1) the VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs:
- 1, 2, 3, respectively, and the VL CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs:
- 4, 5, 6, respectively;
- and
- (2) the VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs:
- 19, 20, 21, respectively, and the VL CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs:
- 22, 23, 24, respectively.
10 more elements
Dependencies are inferred from the claim text.